IVERIC bio, Inc.
IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 compri…
Biotechnology
US, Parsippany [HQ]
ISEE/Financial Reporting
Income Statements
12 Sheets · Starting from 2022In Million USD. Margins, Growth Rates In %
| Metric | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - - | - - | - - | 41.00 | 51.00 | 50.00 | 209.00 | - - | - - | - - | - - | - - | |
|
EPS
|
-0.83 | -0.65 | -5.68 | -2.95 | -3.06 | -5.45 | 3.18 | 1.70 | -1.39 | -1.14 | -1.12 | -1.45 | |
| Diluted in mil. | -0.83 | -0.65 | -5.68 | -2.95 | -3.06 | -5.45 | 3.17 | 1.70 | -1.39 | -1.14 | -1.12 | -1.45 | |
|
Profit
|
- - | - - | - - | 41.00 | 51.00 | 50.00 | 209.00 | - - | - - | - - | - - | - - | |
| Gross Margin | - - | - - | - - | 100.00 | 100.00 | 100.00 | 100.00 | - - | - - | - - | - - | - - | |
| Pre Tax | -19.00 | -14.00 | -51.00 | -80.00 | -122.00 | -193.00 | 109.00 | 62.00 | -58.00 | -88.00 | -114.00 | -185.00 | |
| Profit Margin | - - | - - | - - | -194.61 | -237.85 | -380.73 | 52.15 | - - | - - | - - | - - | - - | |
| ETR | 5.23 | 2.56 | 4.43 | -22.28 | 13.70 | 0.21 | -4.30 | -1.71 | 0.19 | 4.19 | 0.25 | 5.11 | |
| Net | -18.00 | -14.00 | -51.00 | -98.00 | -105.00 | -193.00 | 114.00 | 63.00 | -58.00 | -84.00 | -114.00 | -175.00 | |
| Profit Margin | - - | - - | - - | -237.98 | -205.26 | -379.93 | 54.39 | - - | - - | - - | - - | - - | |
| EBITDA | -19.00 | -14.00 | -49.00 | -80.00 | -121.00 | -193.00 | 112.00 | 62.00 | -61.00 | -88.00 | -114.00 | -192.00 | |
| EBITDA Margin | - - | - - | - - | -194.31 | -236.49 | -379.24 | 53.46 | - - | - - | - - | - - | - - | |
| Operating Income | -19.00 | -13.00 | -47.00 | -80.00 | -123.00 | -195.00 | 108.00 | -65.00 | -61.00 | -88.00 | -114.00 | -189.00 | |
| Operating Margin | - - | - - | - - | -195.14 | -239.84 | -384.14 | 51.44 | - - | - - | - - | - - | - - | |
| Interest Income | - - | - - | -1.00 | - - | - - | 1.00 | 1.00 | 2.00 | 2.00 | - - | - - | 2.00 | |
| Loss | -19.00 | -13.00 | -47.00 | -121.00 | -175.00 | -246.00 | -101.00 | -65.00 | -61.00 | -88.00 | -114.00 | -189.00 | |
| Cost of Revenue | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
|
Operating Expenses
|
-19.00 | -13.00 | -47.00 | -121.00 | -175.00 | -246.00 | -101.00 | -65.00 | -61.00 | -88.00 | -114.00 | -189.00 | |
| R&D | -13.00 | -6.00 | -33.00 | -88.00 | -131.00 | -196.00 | -66.00 | -41.00 | -39.00 | -62.00 | -85.00 | -117.00 | |
| G&A | -5.00 | -6.00 | -14.00 | -33.00 | -44.00 | -50.00 | -35.00 | -23.00 | -21.00 | -25.00 | -29.00 | -72.00 | |
| SG&A | -5.00 | -6.00 | -14.00 | -33.00 | -44.00 | -50.00 | -35.00 | -23.00 | -21.00 | -25.00 | -29.00 | -72.00 | |
| S&M | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Depreciation and Amortization | - - | - - | - - | - - | - - | - - | -2.00 | - - | - - | - - | - - | - - | |
| Interest Expenses | - - | - - | -1.00 | - - | - - | -1.00 | -1.00 | -2.00 | -2.00 | - - | - - | -2.00 | |
| Other Expenses | - - | - - | -3.00 | - - | -1.00 | -1.00 | -1.00 | -127.00 | -2.00 | - - | - - | -4.00 | |
|
WA Shares Outstanding
|
22.00 | 22.00 | 9.00 | 33.00 | 34.00 | 35.00 | 35.00 | 37.00 | 42.00 | 74.00 | 101.00 | 121.00 | |
| Diluted | 22.00 | 22.00 | 9.00 | 33.00 | 34.00 | 35.00 | 36.00 | 37.00 | 42.00 | 74.00 | 101.00 | 121.00 |